Dr Nilsson was formerly Vice-President of Business Development and Chief Scientific Officer with Fujirebio Diagnostics, based in America and Sweden, where he was responsible for the development of the product portfolio and specifically searching out and identifying new in-licensing opportunities for product development. In 1992 Dr Nilsson co-founded CanAg Diagnostics AB through a management buyout from Pharmacia AB. CanAg Diagnostics was acquired by Fujirebio Diagnostics Inc, US in 2006.
Dr Nilsson is a biochemist and immunochemist with more than 25 years academic and industrial experience within different areas of biochemistry and cancer diagnostics based on monoclonal antibodies.
Abcodia has exclusive commercial rights to the UKCTOCS longitudinal biobank that represents one of the largest collections of prospective serum samples in the world. The collection is derived from more than 200,000 initially healthy volunteers, many of whom went on to develop cancer. Using this resource, Abcodia is working with many industrial and academic groups to advance tests for the early detection and screening of cancer.
Dr Julie Barnes, Abcodia’s CEO, said: “Appointing Dr Nilsson as a consultant with his extensive skills and expertise in the commercialisation of biomarkers for cancer builds on our strong team as we continue to drive forward our cancer screening programmes. Having Olle join us is a real endorsement of our work.”
Dr Nilsson added: “I am delighted to be supporting Abcodia at such an exciting time in the company’s development. The market for cancer screening products has enormous potential and the use of the UKCTOCS prospective sample bank for Abcodia’s collaborative cancer screening programmes affords a unique opportunity to make a difference in this exciting field.”
Last year Abcodia swept the board at Startups Awards 2012 in the UK by scooping three top prizes, as well as being honoured as the overall ‘NatWest Startups Business of the Year’, for its pioneering work in cancer screening. It won every award it was shortlisted for.
About Abcodia
Abcodia is a specialist company engaged in the discovery and verification of biomarkers for cancer screening. The prospective biobank that Abcodia has an exclusive licence to has over 5,000,000 serum samples derived from more than 200,000 initially healthy volunteers, 50,000 of whom have provided samples annually, making this an ideal resource for identifying biomarkers for cancer screening. www.abcodia.com
About UKCTOCS
Further details about the United Kingdom Collaborative Trial of Ovarian Cancer Screening can be found at http://www.instituteforwomenshealth.ucl.ac.uk/academic_research/gynaecologicalcancer/gcrc/ukctocs
*******
Media enquiries
Please email [email protected], or contact Press Officer Ellee Seymour on 07939 811961, email [email protected]
____________________________________________